Pretreatment anti-GM-CSF antibody concentrations and surfactant protein (SP) levels according to patient and disease features
| Feature | Anti-GM-CSF Ab (μg/ml) | p value | SP-A (μg/ml) | p value | SP-B (μg/ml) | p value |
|---|---|---|---|---|---|---|
| Values are mean (range). | ||||||
| Age (years) | ||||||
| <32 (n=6) | 208 (51–618) | NS | 2.8 (0.9–6.0) | NS | 16.5 (8.5–37.5) | NS |
| ≥32 (n=6) | 320 (85–410) | 1.3 (0.6–1.7) | 24.6 (9.3–48.9) | |||
| Sex | ||||||
| Male (n=9) | 245 (74–410) | NS | 1.1 (0.6–29.6) | 0.06 | 17.1 (9.3–37.5) | NS |
| Female n=(3) | 216 (51–618) | 2.8 (1.5–6.0) | 20.2 (8.5–48.9) | |||
| Smoker | ||||||
| Never (n=6) | 173 (51–397) | NS | 1.2 (0.9–2.7) | NS | 22.3 (8.5–48.9) | NS |
| Current/previous (n=6) | 274 (85–618) | 2.3 (0.6–6.0) | 18.7 (14.8–33.0) | |||
| Time from diagnosis (months) | ||||||
| ≤28 (n=7) | 245 (51–618) | NS | 2.7 (0.8–6.0) | 0.09 | 14.8 (8.5–22.2) | 0.007 |
| >28 (n=5) | 200 (85–410) | 1.1 (0.6–1.6) | 33.0 (19.3–48.9) | |||
| Prior therapeutic lavage | ||||||
| No (n=3) | 200 (74–397) | NS | 1.0 (0.9–1.7) | NS | 14.5 (9.3–37.5) | NS |
| Yes (n=9) | 245 (51–618) | 1.6 (0.6–6.0) | 19.3 (8.5–48.9) | |||
| Time since lavage (months) | ||||||
| <6 (n=4) | 260 (51–618) | NS | 2.7 (0.8–6.0) | NS | 18.2 (8.5–22.3) | 0.09 |
| ≥6 (n=5) | 245 (85–410) | 1.3 (0.8–3.0) | 31.5 (14.8–48.9) | |||